Uncategorized
Meeting of the CELONKO research project consortium members
On 2 February 2017 the inaugural meeting was held for the research project: Development of modern biomarkers and development of an innovative FGFR kinase inhibitor for the treatment of neoplastic diseases – CELONKO. The meeting included a presentation of the project deliverables to date and the plans for 2017. Aleksandra Stańczak, MD, leader of the OncologyRead more »
Celon Pharma S.A. is a partner of the SMART-UP Lab Project
Celon Pharma S.A. supports talented students, graduates and doctoral students from Polish research centres. This time it is as a partner of the SMART-UP Lab programme which aims at educating young entrepreneurs and developing innovative projects ready for commercial use in the field of health and active life. We value young people who have ambitiousRead more »
Celon Pharma S.A. nominated for the Business Shark (Rekiny Biznesu) Award on the 25th anniversary of the Polish capital market.
The Business Shark is an award given to the best companies and greatest personalities of the 25 years of the Polish capital market. Celon Pharma S.A. was nominated in the “Best debut of the 25 years” category. The official award ceremony will be held on 25 November as part of the Capital Market Forum conference.
Investors want to buy shares for PLN 1.5 billion at Celon Pharma’s IPO.
In the book-building process regaring Celon Pharma S.A.’s IPO which was completed today and was held by Mercurius Dom Maklerski, investors expressed their desire to purchase the Company’s shares for over PLN 1.5 billion, including in the retail tranche almost 2.5 thousand investors offered to buy shares with the value of over PLN 180 million.Read more »
Celon Pharma S.A. commences its IPO
On September 12 a press conference of the Celon Pharma S.A Company took place. During the meeting, representatives of the Management Board presented the business plans for the company related to its public offering of B series shares.
Celon Pharma S.A. is on its way to the stock exchange
29 August The Polish Financial Supervision Authority approved the Prospectus of the Company, which means that its first listing on the Warsaw Stock Exchange may take place this autumn. Celon Pharma S.A. will be the first biopharmaceutical company which at the same time specialises in developing, manufacturing and marketing of specialised generic drugs, as wellRead more »
Celon Pharma at the International CEBC Congress
On 18th June 2016, Celon Pharma S.A. took part in the 2nd Central European Biomedical Congress which was held in Cracow. The theme of this year’s CEBC edition was “From emerging biochemical strategies to personalised medicine”. Aleksandra Stańczak, PhD – leader of the Oncology Research Group in the Celon Pharma S.A. held a lecture entitledRead more »
Celon Pharma S.A. is one of Forbes Diamonds 2016
The company received a prestigious award granted to the most dynamically developing companies in Poland. The award ceremony was held on Wednesday, June 8th 2016. This year’s list includes a total of 440 companies. Celon Pharma S.A. took third place in the medium-sized company category in the Mazowieckie voivodeship and took fourth place in the nationwideRead more »
Celon Pharma S.A. concluded another agreement with the National Centre for Research and Development (NCRD)
On 26 August 2015, Celon Pharma S.A. signed another agreement with the National Centre for Research and Development for the co-financing of a project entitled: “New treatment for psychotic disorders and Huntington’s disease with special focus on cognitive deficits” (NoteSzHD) as part of the STRATEGMED programme. The funds obtained under the agreement will allow CelonRead more »